INKT
Bearish signalScored 2026-10-17 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
MiNK Therapeutics, Inc.
- Nom
- MiNK Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $54.7M
- Employés
- 15
- PDG
- Jennifer S. Buell
- Site web
- https://minktherapeutics.com
- Marché
- CRVOEQGANXHOWLIOBTNRXP
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 6 938 titres (~73 265,28 $ US)
- Insiders
- Buell Jennifer
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$73,265
Avg sell (VWAP, 90d window) $10.56 vs last close $9.56 (-9.5%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-10-12
- Liquidity
- Illiquid $186,513/day · 20d vol
- Last synced
-
2026-10-19 21:10:34
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-12 | Buell Jennifer | Sell · S | 6,938 | $10.56 | $73,265 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-17 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
INKT presents a critically distressed financial profile with zero revenue, negative cash flows, and negative working capital, making the business model appear non-viable at this stage.
The first sentence of the analysis written for INKT on 2026-10-17 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 1.06 · operating margin 0.0%
Suggested stop 9.19, nearest stored support minus 0.5 ATR(3.8% under the last close). Reward/risk to the next stored resistance is 5.32. Research, not advice. Not an order.
Recent news
- 2026-10-02 MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026 NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting. The presentations address two distinct areas of cancer research: tumor-cell killing in checkpoint inhibitor–resistant colorectal cancer liver metastases and elimination of senescent tumor cells and fibroblasts.
- 2026-09-30 MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature
- 2026-08-13 MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript
- 2026-08-13 MiNK Therapeutics Q2 Earnings Call Highlights MiNK Therapeutics NASDAQ: INKT said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and acute respiratory distress syndrome, or ARDS, during the second quarter of 2026.
- 2026-08-13 MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune disorders, today reported financial results for the second quarter ended June 30, 2026, and provided an update on the clinical advancement of its lead candidate, agenT-797.
- 2026-08-06 MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026. The Company will host a conference call and webcast at 8:30 AM ET that morning to review financial results and provide a corporate update focused on the clinical advancement of agenT-797, MiNK''s off-the-shelf allogeneic iNKT cell therapy, in acute lung injury.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 1.063 | 0.717 | 0.316 | 1.609 | 2.407 | |
| Quick Ratio | 1.063 | 0.717 | 0.316 | 1.609 | 2.407 | |
| Solvency Ratio | -0.433 | -0.418 | -0.984 | -1.274 | -1.830 | |
| Cash Ratio | 1.025 | 0.658 | 0.295 | 1.548 | 2.362 | |
| Price To Earnings Ratio | -3.805 | -2.403 | -1.636 | -3.141 | -4.939 | |
| Price To Earnings Growth Ratio | -3.679 | 0.043 | 0.077 | 0.394 | -0.059 | |
| Forward Price To Earnings Growth Ratio | -3.679 | 0.043 | 0.077 | 0.394 | -0.059 | |
| Price To Earnings Diluted Ratio | -3.805 | -2.489 | -1.636 | -3.141 | -4.939 | |
| Price To Earnings Diluted Growth Ratio | -0.820 | 0.044 | 0.077 | 0.394 | -0.059 | |
| Price To Book Ratio | -3.346 | -1.332 | -2.036 | -219.002 | 6.280 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -8.035 | -2.731 | -2.322 | -4.597 | -11.418 | |
| Price To Operating Cash Flow Ratio | -8.035 | -2.731 | -2.332 | -4.658 | -11.640 | |
| Debt To Assets Ratio | 0.364 | 0.861 | 0.000 | 0.000 | 0.000 | |
| Debt To Equity Ratio | -0.364 | -0.251 | 0.000 | 0.000 | 0.000 | |
| Debt To Capital Ratio | -0.572 | -0.336 | 0.000 | 0.000 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.000 | -0.336 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | -1.001 | -0.292 | -0.252 | -53.505 | 1.692 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -0.455 | -1.373 | -1.382 | -1.488 | -0.779 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.005 | 1.013 | 1.019 | |
| Debt Service Coverage Ratio | -2.377 | 0.000 | 0.000 | -110.016 | -11.393 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -122.173 | -7.652 | |
| Short Term Operating Cash Flow Coverage Ratio | -1.144 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -1.144 | -1.940 | 0.000 | 0.000 | 0.000 | |
| Capital Expenditure Coverage Ratio | 0.000 | -2,388,869.000 | -214.278 | -75.453 | -51.518 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | -2,388,869.000 | -214.278 | -75.453 | -51.518 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.202 | -2.502 | -1.501 | -2.449 | -3.986 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 1.063 | ▲0.346 | ▼-0.160 |
| Quick Ratio | 1.063 | ▲0.346 | ▼-0.160 |
| Solvency Ratio | -0.432 | ▼-0.015 | ▲0.555 |
| Cash Ratio | 1.025 | ▲0.368 | ▼-0.152 |
| Price To Earnings Ratio | -3.805 | ▼-1.402 | ▼-0.621 |
| Price To Earnings Growth Ratio | -3.679 | ▼-3.722 | ▼-3.034 |
| Forward Price To Earnings Growth Ratio | -3.679 | ▼-3.722 | ▼-3.034 |
| Price To Earnings Diluted Ratio | -3.805 | ▼-1.316 | ▼-0.603 |
| Price To Earnings Diluted Growth Ratio | -0.820 | ▼-0.863 | ▼-0.747 |
| Price To Book Ratio | -3.346 | ▼-2.014 | ▲40.541 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -8.035 | ▼-5.304 | ▼-2.215 |
| Price To Operating Cash Flow Ratio | -8.035 | ▼-5.304 | ▼-2.156 |
| Debt To Assets Ratio | 0.364 | ▼-0.497 | ▲0.119 |
| Debt To Equity Ratio | -0.364 | ▼-0.113 | ▼-0.241 |
| Debt To Capital Ratio | -0.572 | ▼-0.236 | ▼-0.391 |
| Long Term Debt To Capital Ratio | 0.000 | ▲0.336 | ▲0.067 |
| Financial Leverage Ratio | -1.001 | ▼-0.709 | ▲9.671 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -0.455 | ▲0.918 | ▲0.641 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | ▼-0.007 |
| Debt Service Coverage Ratio | -2.377 | ▼-2.377 | ▲22.380 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲25.965 |
| Short Term Operating Cash Flow Coverage Ratio | -1.144 | ▼-1.144 | ▼-0.915 |
| Operating Cash Flow Coverage Ratio | -1.144 | ▲0.796 | ▼-0.527 |
| Capital Expenditure Coverage Ratio | 0.000 | ▲2388869.000 | ▲477842.050 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | ▲2388869.000 | ▲477842.050 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.202 | ▼-0.701 | ▼-0.474 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $47.6M | $26.1M | $36.8M | $87.9M | $149.3M | |
| Enterprise value | $39.4M | $26.4M | $33.4M | $68.3M | $110.4M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -6.66x | -2.77x | -2.12x | -3.62x | -8.61x | |
| EV / Free cash flow | -6.66x | -2.77x | -2.11x | -3.57x | -8.44x | |
| EV / EBITDA | -3.20x | -2.50x | -1.50x | -2.45x | -3.99x | |
| Net debt / EBITDA | 0.66x | -0.03x | 0.15x | 0.70x | 1.40x | |
| Current ratio | 1.06x | 0.72x | 0.32x | 1.61x | 2.41x | |
| Income quality | 0.47x | 0.89x | 0.70x | 0.67x | 0.42x | |
| Graham net-net | -$4 | -$6 | -$6 | -$1 | $7 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 108.8% | |
| Working capital | $817K | -$2.0M | -$7.8M | $7.7M | $23.2M | |
| Invested capital | $1.2M | -$1.2M | -$6.9M | $8.8M | $23.8M | |
| Return on assets | -87.7% | -188.5% | -493.3% | -130.4% | -75.1% | |
| Operating ROA | -125.1% | -207.3% | -176.2% | -100.3% | -83.1% | |
| Return on tangible assets | -87.7% | -188.5% | -493.3% | -130.4% | -75.1% | |
| Return on equity | 87.8% | 55.1% | 124.4% | 6975.1% | -127.1% | |
| Return on invested capital | -195.5% | 859.7% | 334.6% | -352.2% | -78.3% | |
| Return on capital employed | -1034.2% | 859.7% | 334.6% | -352.2% | -78.3% | |
| Earnings yield | -26.2% | -41.3% | -61.1% | -31.8% | -20.2% | |
| Free cash flow yield | -12.4% | -36.6% | -43.1% | -21.8% | -8.8% | |
| Capex / Op. cash flow | 0.0% | -0.0% | -0.5% | -1.3% | -1.9% | |
| Capex / Depreciation | 0.0% | 0.0% | 36.0% | 205.4% | 319.4% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 6879d | 4622d | 6978d | 17457d | 14025d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -6879d | -4622d | -6978d | -17457d | -14025d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years